Market Access News | pharmaphorum

News

Europe's CHMP recommends AZ's Forxiga in type 1 diabetes

The European Medicines Agency’s CHMP regulatory committee has recommended AstraZeneca’s Forxiga to help adults with type 1 diabetes manage their blood sugar.

News

NICE approves Novartis' CAR-T therapy for diffuse large B-ce...

NICE has approved Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) for diffuse large B-cell lymphoma (DLBCL) in adults who did not respond to two or more previous treatments.

News

FDA finally approves Mylan's Advair generic

The FDA has finally approved the first generic of GlaxoSmithKline’s Advair blockbuster respiratory diseases inhaler, after years of delays.

News

Novo accelerates launch plans for oral semaglutide

Novo Nordisk has said it is accelerating launch preparations for its new diabetes pill semaglutide, after investing in a voucher that will allow a fast review of the drug in the US.

News

Brexit could hinder CAR-T reimbursement in Europe

Brexit and the rise of nationalism in Europe could hinder patients' access to pricey CAR-T therapies across Europe, a conference heard.

News

NICE aims to improve communications with UK life sciences

NICE has announced a collaboration with an organisation representing UK life sciences, to improve communications between the cost-effectiveness body and industry.

Europe's CHMP recommends AZ's Forxiga in type 1 diabetes

NICE approves Novartis' CAR-T therapy for diffuse large B-ce...

FDA finally approves Mylan's Advair generic

Novo accelerates launch plans for oral semaglutide

Brexit could hinder CAR-T reimbursement in Europe

NICE aims to improve communications with UK life sciences

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks